To address the functional role of Tregs in restraining RT + IT efficacy, we opted to implement treatment with a pan-Treg-targeting CD25-depleting antibody (aCD25) (ref. 52) during the response phase of Treg induction in RT + Conc.IT-treated PDG-Ink4a glioblastoma-bearing mice (Extended Data Fig. 7a). Here, CDKN2A is linked to glioblastoma.